Infusion anti-B-cell therapy in multiple sclerosis: a comparative analysis of agents within the same class
Abstract
Given the recent trends and accumulating evidence supporting the advantages of anti-B-cell therapy, early initiation of this treatment modality in multiple sclerosis (MS) has become increasingly relevant for controlling disease activity and reducing the risk of disability progression. The therapeutic landscape for MS continues to expand, with the introduction of a new anti-CD20 molecule – divozilumab – approved in Russia in 2023, which has shown efficacy in patients with MS. When selecting a treatment strategy for MS patients, clinical decisions should be based on the evidence from individual clinical trials and real-world experience, especially for patients with progressive forms of the disease.
Among intravenous anti-CD20 therapies, ocrelizumab currently holds a clinical advantage due to the breadth of real-world experience supporting its use.
About the Authors
A. N. Boiko
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Department of Neuroimmunology, Federal Center for Brain and Neurotechnologies, FMBA of Russia
Russian Federation
Competing Interests:
Russian Federation
Alexey Nikolaevich Boyko
1, Ostrovityanovа St., Moscow 117997;
1, Ostrovityanovа St., Build. 10, Moscow 117997
Competing Interests:
The article is sponsored by Roche. The conflict of interests did not affect the results of the study.
A. D. Kukushkina
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Department of Neuroimmunology, Federal Center for Brain and Neurotechnologies, FMBA of Russia; M.E. Zhadkevich City Clinical Hospital, Moscow Healthcare Department
Russian Federation
Competing Interests:
Russian Federation
1, Ostrovityanovа St., Moscow 117997;
1, Ostrovityanovа St., Build. 10, Moscow 117997;
14, Mozhayskoe Sh., Moscow 121374
Competing Interests:
The article is sponsored by Roche. The conflict of interests did not affect the results of the study.
S. V. Rogovsky
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Department of Neuroimmunology, Federal Center for Brain and Neurotechnologies, FMBA of Russia
Russian Federation
Competing Interests:
Russian Federation
1, Ostrovityanovа St., Moscow 117997;
1, Ostrovityanovа St., Build. 10, Moscow 117997
Competing Interests:
The article is sponsored by Roche. The conflict of interests did not affect the results of the study.
References
1. Cree BAC, Hartung HP, Barnett M. New drugs for multiple sclerosis: new treatment algorithms. Curr Opin Neurol. 2022 Jun 1;35(3):262-70. doi: 10.1097/WCO.0000000000001063
2. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis world-wide: Insights from the Atlas of MS, third edition. Mult Scler. 2020 Dec;26(14):1816-21. doi: 10.1177/1352458520970841. Epub 2020 Nov 11.
3. Jain RW, Yong VW. B cells in central nervous system disease: diversity, locations and pathophysiology. Nat Rev Immunol. 2022 Aug;22(8):513-24. doi: 10.1038/s41577-021-00652-6. Epub 2021 Dec 13.
4. Kee R, Naughton M, McDonnell GV, et al. A Review of Compartmentalised Inflammation and Tertiary Lymphoid Structures in the Pathophysiology of Multiple Sclerosis. Biomedicines. 2022 Oct 17;10(10):2604. doi: 10.3390/biomedicines10102604
5. Moccia M, Ruggieri S, Ianniello A, et al. Advances in spinal cord imaging in multiple sclerosis. Ther Adv Neurol Disord. 2019 Apr 22;12:1756286419840593. doi: 10.1177/1756286419840593
6. Moccia M, Haider L, Eshaghi A, et al. B Cells in the CNS at Postmortem Are Associated With Worse Outcome and Cell Types in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 10;9(1):e1108. doi: 10.1212/NXI.0000000000001108
7. Instructions for medical use of the medicinal product Ocrelizumab. LP-No. (003473)-(RG-RU)-201023 (In Russ.).
8. Instructions for medical use of the medicinal product Divosilimab. LP-No. (002035)-(RG-RU)-100325 (In Russ.).
9. Instructions for medical use of the medicinal product Ofatumumab. LP-No. (001332)-(RG-RU)-060923 (In Russ.).
10. Comi G, Bermel R, Bar-OR A, et al. A multicentre, open label, single-arm, phase 3b study (CONSONANCE) to assess the effectiveness and safety of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year-1 interim analysis (P1-1.Virtual) Neurology. Ovid Technologies (Wolters Kluwer Health). 2022;98(18 Suppl).
11. Hauser SL, Bar-Or A, Comi G, et al; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):221-34. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.
12. Hauser S, Kappos L, Filippi M, et al. 10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-term Efficacy and Safety Clinical Trial Data (S31.005) Neurology. Ovid Technologies (Wolters Kluwer Health). 2024;102(17 Suppl 1).
13. Wolinsky JS, Arnold DL, Brochet B, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2020 Dec;19(12):998-1009. doi: 10.1016/S1474-4422(20)30342-2. Epub 2020 Oct 29. Erratum in: Lancet Neurol. 2021 Jan;20(1):e1. doi: 10.1016/S1474-4422(20)30437-3
14. Juanatey A, Blanco-Garcia L, Tellez N. Ocrelizumab: its efficacy and safety in multiple sclerosis. Rev Neurol. 2018 Jun 16;66(12):423-33.
15. Kappos L, Traboulsee A, Li DKB, et al. Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension. J Neurol. 2024 Feb;271(2):642-57. doi: 10.1007/s00415-023-11943-4. Epub 2023 Oct 31.
16. Boyko AN, Davydovskaya MV, Khachanova NV, et al. Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3):16-25. doi: 10.14412/2074-2711-2019-3-16-25 (In Russ.).
17. Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol. 2020 Sep 1;77(9):1132-40. doi: 10.1001/jamaneurol.2020.1568
18. Wolinsky JS, Narayana PA, O'Connor P, et al; PROMiSe Trial Study Group. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007 Jan;61(1):14-24. doi: 10.1002/ana.21079
19. Montalban X, Sastre-Garriga J, Tintore M, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler. 2009 Oct;15(10):1195-205. doi: 10.1177/1352458509106937. Epub 2009 Sep 29.
20. Tur C, Montalban X, Tintore M, et al. Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up. Arch Neurol. 2011 Nov;68(11):1421-7. doi: 10.1001/archneurol.2011.241
21. Hawker K, O'Connor P, Freedman MS, et al; OLYMPUS trial group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009 Oct;66(4):460-71. doi: 10.1002/ana.21867
22. Lublin F, Miller DH, Freedman MS, et al; INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 12;387(10023):1075-84. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28. Erratum in: Lancet. 2017 Jan 21;389(10066):254. doi: 10.1016/S0140-6736(17)30042-9
23. Montalban X, Hauser SL, Kappos L, et al; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209-20. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.
24. Derfuss T, Bermel R, Lin CJ, et al. Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials. Ther Adv Neurol Disord. 2024 Oct 8;17:17562864241277736. doi: 10.1177/17562864241277736
25. Данные компании Roche. Progressive multifocal leukoencephalopathy. Available at: https://www.ocrelizumabinfo.global/en/home-page/safety-topics/progressive-multifocal.html#narratives (accessed 08.04.2025).
26. Boyko AN, Alifirova VM, Lukashevich IG, et al. Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebocontrolled clinical trial BCD-132-4/MIRANTIBUS. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(7-2):43-52. doi: 10.17116/jnevro202312307243 (In Russ.).
27. Boyko AN, Alifirova VM, Lukashevich IG, et al. Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4):86-96. doi: 10.17116/jnevro202412404186 (In Russ.).
28. Clinical guidelines for multiple sclerosis, approved by the Ministry of Health of the Russian Federation, version 13.07.2022 (In Russ.).
29. Konen FF, Möhn N, Witte T, et al. Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. Autoimmun Rev. 2023 May;22(5):103312. doi: 10.1016/j.autrev.2023.103312. Epub 2023 Mar 15.
Review
For citations:
Boiko AN, Kukushkina AD, Rogovsky SV. Infusion anti-B-cell therapy in multiple sclerosis: a comparative analysis of agents within the same class. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. (In Russ.)
Views:
6
Email this article 